Abstract: AIM: To compare the therapeutic efficacy and safety of use of exclusive long-term Teprenone, Misoprostol and Omeprazole to prevent recurrence of NSAIDs-related ulcer. METHODS: 107 cases of patients with NSAIDs-related ulcer were enrolled and randomly divided into three groups after cured by 6-8 weeks treatment: The therapeutic Teprenone group(38 cases)was followed by the treatment with long-term use Teprenone (50 mg,tid). the Omeprazole group (34 cases) by the exclusive long-term use of Omeprazole (20 mg,bid);and the Misoprostol group (35 cases) by the exclusive long-term use of misoprostol (200 μg,bid). During the treatment course of 52 weeks,incidence rates of ulcer recurrence and adverse reactions of the three groups were measured at the 26^th and 52^th week. RESULTS: During the period of the first 26 weeks,recurrence cases of the three groups were 5(13.2%),5(14.3%) and 4(11.8%),respectively;there was no statistically significant difference among the three groups(P＞0.05);and the cases during the period of the 27^th and 52^th weeks were 6(18.2%), 3(10.0%) and 4(13.3%),respectively,with no statistically difference among the three groups(P＞0.05). Incidence rates of adverse reactions were 5(13.2%),4(11.4%)and 12(35.3%)in the three groups respectively during the period of the first 26 weeks,with no statistically significant between Omeprazole and Teprenone groups(P＞0.05);but the rate in the Misoprotol group was significantly higher than the other two groups(P＜0.05). From the 27^th week to the 52^th week,adverse reaction rates were 3(9.1%),9(30.0%) and 10(33.3%),respectively, with the rate in Teprenone group was significantly lower than the other two groups(P＜0.05). CONCLUSION: Long-term Teprenone is equivalent to PPI or Misoprotol in preventing the recurrence of NSAIDs-related ulcer,and adverse reaction is reduced.

Key words: NSAIDs, Teprenone, Omeprazole, Misoprostol, Peptic ulcer, Recurrence